A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
for Parkinson's Disease
Drug: Prasinezumab
42 locations incl. Birmingham
Sponsor: Hoffmann-La Roche
Sex: All·Age: 50 - 85
Code: NCT07174310·Phase 3·Recruiting